Cargando…
Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations
AIM: To systematically identify and appraise the international literature on the cost-effectiveness of metabolic surgery for the treatment of comorbid type 2 diabetes (T2D) and obesity. METHODS: A systematic search was conducted in electronic databases and grey literature sources up to 20 January 20...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175448/ https://www.ncbi.nlm.nih.gov/pubmed/35869383 http://dx.doi.org/10.1007/s10198-022-01494-2 |
_version_ | 1785040215253975040 |
---|---|
author | Jordan, Karen Fawsitt, Christopher G. Carty, Paul G. Clyne, Barbara Teljeur, Conor Harrington, Patricia Ryan, Mairin |
author_facet | Jordan, Karen Fawsitt, Christopher G. Carty, Paul G. Clyne, Barbara Teljeur, Conor Harrington, Patricia Ryan, Mairin |
author_sort | Jordan, Karen |
collection | PubMed |
description | AIM: To systematically identify and appraise the international literature on the cost-effectiveness of metabolic surgery for the treatment of comorbid type 2 diabetes (T2D) and obesity. METHODS: A systematic search was conducted in electronic databases and grey literature sources up to 20 January 2021. Economic evaluations in a T2D population or a subpopulation with T2D were eligible for inclusion. Screening, data extraction, critical appraisal of methodological quality (Consensus Health Economic Criteria list) and assessment of transferability (International Society for Pharmacoeconomics and Outcomes Research questionnaire) were undertaken in duplicate. The incremental cost-effectiveness ratio (ICER) was the main outcome. Costs were reported in 2020 Irish Euro. Cost-effectiveness was interpreted using willingness-to-pay (WTP) thresholds of €20,000 and €45,000/quality-adjusted life year (QALY). Due to heterogeneity arising from various sources, a narrative synthesis was undertaken. RESULTS: Thirty studies across seventeen jurisdictions met the inclusion criteria; 16 specifically in a T2D population and 14 in a subpopulation with T2D. Overall, metabolic surgery was found to be cost-effective or cost-saving. Where undertaken, the results were robust to sensitivity and scenario analyses. Of the 30 studies included, 15 were considered high quality. Identified limitations included limited long-term follow-up data and uncertainty regarding the utility associated with T2D remission. CONCLUSION: Published high-quality studies suggest metabolic surgery is a cost-effective or cost-saving intervention. As the prevalence of obesity and obesity-related diseases increases worldwide, significant investment and careful consideration of the resource requirements needed for metabolic surgery programmes will be necessary to ensure that service provision is adequate to meet demand. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-022-01494-2. |
format | Online Article Text |
id | pubmed-10175448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-101754482023-05-13 Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations Jordan, Karen Fawsitt, Christopher G. Carty, Paul G. Clyne, Barbara Teljeur, Conor Harrington, Patricia Ryan, Mairin Eur J Health Econ Original Paper AIM: To systematically identify and appraise the international literature on the cost-effectiveness of metabolic surgery for the treatment of comorbid type 2 diabetes (T2D) and obesity. METHODS: A systematic search was conducted in electronic databases and grey literature sources up to 20 January 2021. Economic evaluations in a T2D population or a subpopulation with T2D were eligible for inclusion. Screening, data extraction, critical appraisal of methodological quality (Consensus Health Economic Criteria list) and assessment of transferability (International Society for Pharmacoeconomics and Outcomes Research questionnaire) were undertaken in duplicate. The incremental cost-effectiveness ratio (ICER) was the main outcome. Costs were reported in 2020 Irish Euro. Cost-effectiveness was interpreted using willingness-to-pay (WTP) thresholds of €20,000 and €45,000/quality-adjusted life year (QALY). Due to heterogeneity arising from various sources, a narrative synthesis was undertaken. RESULTS: Thirty studies across seventeen jurisdictions met the inclusion criteria; 16 specifically in a T2D population and 14 in a subpopulation with T2D. Overall, metabolic surgery was found to be cost-effective or cost-saving. Where undertaken, the results were robust to sensitivity and scenario analyses. Of the 30 studies included, 15 were considered high quality. Identified limitations included limited long-term follow-up data and uncertainty regarding the utility associated with T2D remission. CONCLUSION: Published high-quality studies suggest metabolic surgery is a cost-effective or cost-saving intervention. As the prevalence of obesity and obesity-related diseases increases worldwide, significant investment and careful consideration of the resource requirements needed for metabolic surgery programmes will be necessary to ensure that service provision is adequate to meet demand. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-022-01494-2. Springer Berlin Heidelberg 2022-07-22 2023 /pmc/articles/PMC10175448/ /pubmed/35869383 http://dx.doi.org/10.1007/s10198-022-01494-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Jordan, Karen Fawsitt, Christopher G. Carty, Paul G. Clyne, Barbara Teljeur, Conor Harrington, Patricia Ryan, Mairin Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations |
title | Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations |
title_full | Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations |
title_fullStr | Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations |
title_full_unstemmed | Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations |
title_short | Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations |
title_sort | cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175448/ https://www.ncbi.nlm.nih.gov/pubmed/35869383 http://dx.doi.org/10.1007/s10198-022-01494-2 |
work_keys_str_mv | AT jordankaren costeffectivenessofmetabolicsurgeryforthetreatmentoftype2diabetesandobesityasystematicreviewofeconomicevaluations AT fawsittchristopherg costeffectivenessofmetabolicsurgeryforthetreatmentoftype2diabetesandobesityasystematicreviewofeconomicevaluations AT cartypaulg costeffectivenessofmetabolicsurgeryforthetreatmentoftype2diabetesandobesityasystematicreviewofeconomicevaluations AT clynebarbara costeffectivenessofmetabolicsurgeryforthetreatmentoftype2diabetesandobesityasystematicreviewofeconomicevaluations AT teljeurconor costeffectivenessofmetabolicsurgeryforthetreatmentoftype2diabetesandobesityasystematicreviewofeconomicevaluations AT harringtonpatricia costeffectivenessofmetabolicsurgeryforthetreatmentoftype2diabetesandobesityasystematicreviewofeconomicevaluations AT ryanmairin costeffectivenessofmetabolicsurgeryforthetreatmentoftype2diabetesandobesityasystematicreviewofeconomicevaluations |